NCT03406247View on ClinicalTrials.gov

Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

February 12, 2018

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Nivolumab

"Patients in cohorts 1 and 1bis will be administered Nivolumab 240 mg every 2 weeks during 3 first months and then 480 mg every 4 weeks during 3 months Patients in cohorts 2 and 2bis will be administered~\- nivolumab 240 mg every 2 weeks during 6 months"

DRUG

Ipilimumab

"Patients in cohorts 2 and 2bis will be administered~\- ipilimumab 1mg/kg IV every 6 weeks during 6 months"

Trial Locations (1)

94805

RECRUITING

Gustave Roussy, Villejuif

All Listed Sponsors
lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER